Abiopharma

PureTech Health: Notice of Half-Yearly Results

Best Bedroom TV Options in 2025

The Blenders With The Best Reviews In 2025

Best Bird Photography Camera Models for Wildlife Enthusiasts in 2025

New Novartis ESC data highlights strength of cardiovascular portfolio

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab Announces Participation in Investor Conferences in June 2025

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab Complies with the HFCAA; Not Subject to Delisting*

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: 180 Life Sciences Corp. - Warrant.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Ontrak, Inc. - Common Stock.